References to Primary Literature
- ROSENBERG PS: Scope of the AIDS epidemic in the United States. Science (1995) 270:1372–1375.
- MULDER D, NUNN A, KAMALI A, KENGEYA-KAYONDO J: Decreasing HIV-1 seroprevalence in young adults in a rural Ugandan cohort. BMJ (1995) 311(7009): 833–836.
- HO DD et at: Rapid turnover of plasma virions and CD4 lymphocytes in 11IV-1 infection. Nature (1995) 373:123–126.
- WEI X et at: Viral dynamics in human immunodefi-ciency virus type 1 infection. Nature (1999 373:117–122.
- Merck exercises remaining naked DNA vaccine options. Vicat Inc. Press Release (1995).
- KAMEOKA M, NISHINO Y, MATSUO K, OHARA N, KIMURA T, YAMAZAKI A, YAMADA T, IKUTA K. Cytotoxic T lym-phocyte response in mice induced by a recombinant BCG vaccine containing estracellulas alpha antigen fused with the human immunodeficiency virus type 1 envelope V3 loop immunodominant domain. Vaccine (1994) 12(2):153–158.
- Viagene's liW product in Phase IL Scrip (1994) 1984:27.
- FLOTTE TR, AFIONE SA, CONRAD C, MCGRATH SA, SOLOW R, OKA H, ZEITLIN PL, GUGGINO WB, CARTER BJ: Stable in vivo expression of the cystic fibrosis trans-membrane conductance regulator with an adeno-asso-dated virus vector. Proc. Natl. Acad. Sci. USA (1993) 90(22):10613–10617.
- Targeted Genetics 1994 Annual Report. (1994).
- Second quarter report, Genetic Therapy. Company Com-munication (1993).
- TUNG FYT, DANIEL MD: Targeted inhibition of immu-nodeficiency virus replication in lymphocytes through retroviral mediated gene transfer. Arch. Vit.& (1993) 133(3-4):407–421.
- TUNG FYT, DANIEL MD: Targeted inhibition of immu-nodeficiency virus replication in lymphocytes through retroviral mediated gene transfer. Arch. Virol. (1993) 133:407–421.
- Process for the preparation of human cells expressinga therapeutic protein. Exp. Opin. Ther. Patents (1995) 5(7):697–699.
- VANDENDRIESSCHE T, CHUAH MK, CHIANG L, CHANGHK, ENSOLI B, MORGAN RA: Inhibition of clinical human immunodeficiency virus (IIW) type 1 isolates in pri-mary CD4+ T lymphocytes by retroviral vectors ex-pressing anti-HIV genes. J. Virol. (1995) 69(7): 4045–4052.
- BERKHOUT B, VAN-WAMEL JL: Inhibition of human immunodeficiency virus expression by sense tran-scripts encoding the retroviral leader RNA. Antiviral Res. (1995) 26(2):101–115.
- LEAVITT MC, YU M, YAMADA 0, DRAUS G, LOONEY D,POESCHLA E, WONG-STAAL F: Transfer of an anti-HIV ribozyme gene into primary human lymphocytes . Hum. Gene Then (1994) 5(9)1115–1120.
- YU M, POESCHLA E, YAMADA 0, DEGRANDIS P, LEAVITTMC, JEUSCH M, YEES JK, WONG-STAAL F, HAMPEL A: In vitro and in vivo characterization of a second functional hairpin ribozyme against 11IV-1. Virology (1 9 9 5) 206(1):381–386.
- LISZIEWICZ J, SUN D, TRAPNELL B, THOMSON M, CHANG HK, ENSOLI B, PENG B: An autoregulated dual function anti tat gene for human immunodeficiency virus type 1 gene therapy. J. Virol (1995) 69(1):206–212.
- LEE SW, GALLARDO HF, GILBOA E, SMITH C: Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virot (1994) 68(12):8254–8264.
- ZHOU C, BAHNER IC, LARSON GP, ZAIA JA, ROSSID, KOHN EB: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene (1994) 149(1):33–39.
- AGUILAR-CORDOVA E, CHINEN J, DONEHOWER LA, HAR-PER JW, RICE AP, BUTEL JS, BELMONT JW: Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther. (1995) 2(3):181–186.
- MHASHILKAR AM, BAGLEY J, CHEN SY, SZILVAY AM,HELLAND DG, MARASCO WA: Inhibition of HIV-1 Tat-me-diated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. (1 9 9 5) 14(7):1542–1551.
- LAU'RET E, VIELLARD V, ROUSSEAU V, DE-MAEYER-GUIG-NARD J, DE-MAEYER E: Exploring interferon beta for gene therapy of IIW infection. Res. Immunot (1994) 145(8–9):674-677; discussion 677–678.
- MORGAN RA, BALER-13111ERLICH G, TAGHEB JA, WONG-STAAL F, GALLO RC, ANDERSON WF: Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human periph-eral blood lymphocytes from infection by HIV type 1. AIDS Res. Hum. Retroviruses (1994) 10(11)1507–1515,
- FURUTA RA, KUBOTA 5, MAKI M, MIYAZAKI Y, HATTORIT, HATANAKA M: Use of human Immunodeficiency virus type 1 Rev mutant without nueleolar dysfunction as a candidate for potential AIDS therapy. J. Virol. (1995) 69(3):1591–1599.
- WOFFENDIN C, YANG ZY, UDZYKUMAR, XU L, YANG NS,
- SHEEHY MJ, NABEL GJ: Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T-cells. Proc. Natl. Acad. Sci. USA (1994) 91(24):11581–11585.
References to Patent Literature
- DANA FARBER CANCER INST., INC., W09418832 (1994).
- BRITISH BIOTECH LTD., '0709420621 (1994).
- THEREXSYS LTD., et al, W09508635 (1995).
- COHEN-HAGUENAUER 0, W09501447 (1995).
- CYTEX CORPORATION, W09510265 (1995).
- RHONE-POULENC RORER SA, W09514102 (1995).
- TARGETED GENETICS CORP., et al., W09513365 (1995).
- SERPIC, et al., W09525542 (1995).